Movatterモバイル変換

[0]ホーム

Jump to content

Citatuzumab bogatox

Edit links

From Wikipedia, the free encyclopedia

Pharmaceutical drug

Pharmaceutical compound

Citatuzumab bogatox
Monoclonal antibody
Type	Fab fragment
Source	Humanized (frommouse)
Target	TACSTD1
Clinical data
ATC code	none
Identifiers
CAS Number	945228-49-9^N
ChemSpider	none
UNII	23J303Z5CA
Chemical and physical data
Formula	C₃₄₅₅H₅₃₇₁N₉₂₁O₁₀₆₀S₁₈
Molar mass	77348.44 g·mol⁻¹
^NY (what is this?) (verify)

Citatuzumab bogatox (VB6-845) is amonoclonal antibody Fab fragment fused with bouganin,^[1] aribosome inactivating protein from the plantBougainvillea spectabilis.^[2] It has undergonepreclinical development for the treatment ofovarian cancer and other solid tumors.^[3]

References

[edit]

^Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M (2018). "Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update".Current Cancer Drug Targets.18 (9):857–868.doi:10.2174/1568009618666180102102311.PMID 29295696.
^International Nonproprietary Names for Pharmaceutical Substances (INN),World Health Organization.
^"VB6-845".Viventia Biotech Inc. Archived fromthe original on 29 March 2010.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Citatuzumab_bogatox&oldid=1307825533"

Categories:

Hidden categories:

[8]ページ先頭